BELLUS Health has economic interests in other partnered clinical-stage drug development programs, including revenue sharing and royalties on sales.

Those programs include KIACTA™ which was sold/licensed to Auven Therapeutics for the treatment of pulmonary sarcoidosis, AMO-01 which was licensed to AMO Pharma Limited (AMO Pharma) for the treatment of Phelan McDermid syndrome and ALZ-801 which was licensed to Alzheon Inc. (Alzheon) for the treatment of Alzheimer’s disease (AD).

  • Auven Therapeutics is currently evaluating whether to further pursue the development of KIACTA™ for the treatment of pulmonary sarcoidosis. Auven Therapeutics has developed a clinical Phase 2/3 study protocol to evaluate the safety and efficacy of KIACTA™ in pulmonary sarcoidosis. The U.S. Food and Drug Administration has cleared the investigational new drug application (IND) for this clinical Phase 2/3 study.
  • AMO Pharma announced in May 2018 the initiation of patient recruitment in an interventional (Phase 2) study of AMO-01 in the treatment of Phelan-McDermid syndrome, a rare genetic condition caused by a chromosomal deletion.
  • Alzheon has completed two Phase 1b clinical studies with ALZ-801 and is currently in preparation for further late-stage clinical studies focusing on treatment of mild AD patients who are homozygous for APOE4, the most important genetic risk factor for late-onset AD.

Share this

Sign up for email alerts

Email Address *
Enter the code shown above.